Redmile Group, a hedge fund and private equity manager, led a $118m Series B round in Shattuck Labs, a clinical-stage biotechnology company, with participation from Janus Henderson Investors, Fidelity Management & Research Company, EcoR1 Capital, Hatteras Venture Partners, Avidity Partners, Partner Fund Management, Emerson Collective and Piper Sandler. "Over the past four years we have pioneered the development of our proprietary ARC technology platform, which consolidates checkpoint blockade and tumor necrosis factor receptor superfamily (TNFRSF) agonism into single therapeutics, tackling many of the risks associated with a new biologics platform along the way. The support from this syndicate of experienced life science investors will accelerate clinical development of multiple programs aimed to establish ARC therapeutics as an entirely new class of biologic medicine," Taylor Schreiber, Shattuck CEO.